Market Intelligence
Healthcare Research and Development Organizations Industries Germany

Germany Healthcare Genomics

Executive Summary

Germany is quickly becoming one of Europe’s most important genomics markets. It already has the largest med-tech market in Europe and the third largest globally with numerous factors driving the demand in med-tech innovations and increasing demand for genomics applications. Germany’s precision medicine and genomics market is currently estimated to be worth approximately USD 4.8 billion.

In recent years, the German genomics market has started to emerge as a leading biotechnology hub in Europe, which is largely due to reimbursement, national data infrastructure and clinical research: Germany’s research focus on genome sequencing is transitioning from next-generation sequencing analysis (NGS) to applied clinical workflows, particularly in oncology and the study of rare diseases. Germany already has meaningful bioinformatics and data infrastructure depth: ELIXIR Germany, set up by the Federal Ministry of Education and Research (BMBF), consists of eight service units of bioinformatics and reports 23 contractual partners from German universities and research institutions.

As various initiatives and projects show, the strongly federated nature of Germany’s genomic infrastructure creates short-term and long-term demand for secure analytics and frameworks under the condition that new services and products introduced to Germany comply with existing innovations and prove to make economic sense. This creates opportunities for U.S. companies in sequencing platforms, clinical decision support, secure data management and analytics, cloud infrastructure, In-Vitro Diagnostics (IVD) development and medical consumables.  

Market Landscape  

The rapid advance in genomic technology and the rising number of chronic illness and cancer diagnoses (500,000 per year) further contribute to market growth. Berlin, Munich and Heidelberg are key players in the genomics industry; Berlin as the center of biotechnology research, Munich as a hub for pharmaceutical companies and Heidelberg with the German Cancer Research Center (DKFZ). Patient data is collected and anonymized by these partner hospitals, which can later be accessed by authorized users and institutes to advance their research and improve care, especially in oncogenomic diagnostics.

In 2021, the requirement for prior authorization for sequencing analysis by public health insurers was removed, which significantly helped to grow the German market and prompt more research. While patients are already reimbursed for NGS analysis, the implementation of reimbursement for clinical whole-genome sequence (WGS) analysis conducted at selected reference hospitals started in 2024. The introduction of reimbursement for clinical WGS represents an important step toward broader clinical adoption and commercialization. The University Hospital Tübingen became the first institute accredited to perform clinical WGS with the Ge-Med Project, which analyzes data by generating polygenic risk scores.  

The national genomDE initiative’s goal is to establish a Germany-wide digital platform and standardized framework for medical genome sequencing and constitutes Germany’s main strategy for genomics. It specifically focuses on oncology and rare diseases. This national strategy is part of larger European efforts, with Germany being a critical player in the 1+ Million Genomes (1+MG) initiative and the European Genomic Data Infrastructure (GDI). The genomDE pilot program, funded by the Federal Ministry of Health (BMG), has two primary goals, that of building a reliable data infrastructure and developing a concept for a secure data processing environment.

On a broader scale, the European Health Data Space (EHDS) was introduced by the European Commission in 2022 to enhance the use of health data, both nationally and internationally, for healthcare and research purposes. A respective EU regulation came into effect in March 2025. Beginning in March 2031, this regulation will also apply to the secondary use of genomic data.

Opportunities for U.S. Companies

The long-term visions of Germany’s genomDE strategy include participation of the pharmaceutical industry, specific promotion of translational medical research, and a strong connection to digital health initiatives.  

The growing market and rapid technological advances in genomics are creating demand for specialized talent that currently exceeds available workforce capacity. This is an opportunity for U.S. companies and experts looking for ways to enter the German market. German health insurance companies have announced that they would allocate a budget of €700 million.

The transition from NGS to WGS requires immense scaling of testing and sequencing capacities. U.S. companies can provide sequencing platforms, automated library preparation tools and can supply major laboratories upgrading their diagnostic infrastructure. This presents an opportunity for In-Vitro Diagnostics (IVD) manufacturers to use Real-World Data (RWD) to establish the efficacy of their devices and for companies conducting oncology and rare disease trials. IVD manufacturers also gain greater product visibility, expanded reimbursement opportunities, and increased commercial opportunities. 

Currently, Germany  has a growing network of six Genome Data Centers in Germany which are all part of the German Human Genome-Phenome Archive (GHGA). The existing infrastructure provides a foundation for future expansion. Processing and storing data rely on technical infrastructure built for high performance. The sensitive nature of the collected data and complying with strict national and European data privacy regulations require secure computation, AI-driven software and cloud environments. In this context, data security becomes increasingly important and presents an opportunity for U.S. companies.

U.S. software providers may enter the German market through licensing agreements, strategic partnerships, and collaborations with healthcare providers and research institutions. Furthermore, decision support software that is compatible with other clinical and diagnostic software will help health care providers in implementing the latest innovations into their practice. This is also helped by showcasing that U.S. products and services fit into the reimbursement-based purchasing system in Germany.  

The German market values not only the quality of innovation, but also the degree to which such innovations can be reliably and economically used. Thus, it is of high importance to comply with CE and EU Medical Device Regulations (MDR). Planning carefully and executing locally is the key to unlocking German – and by extension –European market credibility.  

Germany’s genomics sector is transitioning from a research-driven environment toward broader clinical implementation, particularly in oncology and rare disease diagnostics. Supported by national initiatives such as genomDE, expanding reimbursement mechanisms, and European data-sharing frameworks, the market is expected to continue growing over the coming decade. U.S. companies with expertise in sequencing technologies, bioinformatics, secure data infrastructure, AI-enabled analytics, and clinical decision support are well positioned to participate in this expansion, provided they align with Germany’s regulatory, reimbursement, and data protection requirements.

German Institutions & Initiatives

  • The Ge-Med Project at the University Hospital of Tübingen has been evaluating whole-genome sequencing (WGS) since 2021.
  • The German Human Genome-Phenome Archive (GHGA): Involved in establishing a German node for the GDI project to make data accessible in a secure manner. GHGA is part of Germany’s National Research Data Infrastructure (NFDI).
  • Max Planck Institute for Molecular Genetics: Renowned research institute for molecular genetics based in Berlin.  
  • German Cancer Research Center (DKFZ): The leading national research institute in Heidelberg.
  • BioNTech: A biotech company headquartered in Mainz, it specializes in immunology, deep genomics and artificial intelligence.  
  • Eppendorf, a biotech company, provides tools for genomics and sample preparation for NGS.  
  • Eurofins Genomics Germany GmbH has laboratories throughout Germany as part of the parent company’s (EUROFINS Group) network of 900 laboratories in 60 countries.  

European Frameworks & Collaborations

  • 1+Million Genomics Initiative: Germany is a member of the European project since 2020.
  • European GDI Project: The Genomic Data Infrastructure project is a collaboration between national authorities, research organizations and technology providers in 20 countries.
  • ELIXIR: Connects German bioinformatics infrastructure to European standards and services.  

Trade Shows:  

  • MEDICA in Düsseldorf: World’s largest Med-Tech trade fair.
  • Analytica in Munich: World’s leading fair for laboratory, biotechnology and analysis.
  • ESCMID Global in Munich: Congress of the European Society of Clinical Microbiology and Infectious Disease.

 

U.S. DEPARTMENT OF COMMERCE, INTERNATIONAL TRADE ADMINISTRATION CONTACT INFORMATION

For additional information, please contact:

Ulrike Riegeler
Commercial Specialist 
U.S. Commercial Service 
Ulrike.Riegeler@trade.gov
+49 69 7535 3157
Frankfurt, Germany